Browse the evidence

Alternate-day modified fasting (ADMF) improves subjective sleep quality (SSQ) and reduces daytime dysfunction compared to daily calorie restriction, but does not significantly change total sleep quality (PSQI) or daytime sleepiness (ESS).

If you are an overweight woman, ADMF may help you feel more rested during the day and improve your subjective sense of sleep quality, even if it doesn't change your total sleep score or daytime sleepiness levels. Focus on the daytime benefits rather than just sleep duration.

Static energy balance models (e.g., the 3500 kcal rule) significantly overestimate weight loss because they ignore adaptive thermogenesis, which causes resting energy expenditure to drop beyond what is explained by the loss of metabolically active tissue.

If you are dieting and hitting a plateau despite strict adherence to a calorie deficit, do not simply slash calories further. Your body has likely triggered adaptive thermogenesis, lowering your metabolic rate to protect fat stores. Recognize this as a biological defense mechanism, not a personal failure. Sustainable weight management may require longer adaptation periods or strategies that preserve fat-free mass, rather than aggressive restriction.

Metabolic adaptation (adaptive thermogenesis) is dynamic and largely reversible; it persists during negative energy balance but diminishes or disappears during weight stability or positive energy balance (refeeding).

Once you stop losing weight and reach your goal weight, your metabolic rate may partially recover if you maintain that weight. However, if you regain weight, the metabolic adaptation may return. Long-term maintenance requires accepting that your maintenance calories may be lower than before your weight loss, due to the loss of metabolically active tissue (FFM).

Intermittent fasting significantly improves lipid profiles by reducing total cholesterol and LDL, but may temporarily increase triglycerides in short-term interventions (≤ 12 weeks).

Intermittent fasting improves total cholesterol and LDL, key markers for heart health. However, be aware that triglycerides may temporarily rise in the first 12 weeks as your body adapts. This is often a transient phase. If you have high baseline triglycerides, consult a healthcare provider and consider longer-term adherence to see the full lipid benefits.

Intermittent fasting significantly reduces diastolic blood pressure but has no significant effect on systolic blood pressure, fasting plasma glucose, or HbA1c in overweight and obese adults.

Intermittent fasting can help lower diastolic blood pressure, a key component of heart health. However, it may not significantly affect systolic blood pressure or blood sugar levels (FPG, HbA1c) in the short term. For comprehensive cardiometabolic health, combine IF with other lifestyle interventions and monitor your specific markers.

Intermittent Energy Restriction (IER) combined with High-Intensity Interval Training (HIIT) produces greater reductions in body weight, body fat percentage, waist circumference, and hip circumference compared to Continuous Energy Restriction (CER) combined with HIIT in overweight/obese adults, although the difference is not statistically significant in a 4-week trial.

If you are overweight or obese, combining High-Intensity Interval Training (HIIT) with an Intermittent Energy Restriction (IER) diet may help you lose more weight and body fat than a standard daily calorie-restricted diet over a short period. Specifically, eating only 30% of your daily calorie needs on two non-consecutive days a week, while eating normally on the other five days, resulted in nearly double the weight loss (4.6 kg vs 2.5 kg) compared to eating 70% of your needs every day. Although the difference wasn't statistically significant in this small 4-week study, the trend favors IER for body composition improvements.

Three-year mild caloric restriction (approx. 100 kcal/day deficit) significantly reduces plasma levels of L-leucine, L-phenylalanine, and sphingomyelin (SM d18:0/16:1) in overweight and obese middle-aged adults, independent of total weight loss magnitude.

To improve metabolic health markers like insulin sensitivity and reduce specific risk metabolites (sphingomyelin, BCAAs), aim for a modest, sustainable daily calorie deficit of about 100 calories rather than extreme restriction. This approach, maintained over years, has been shown to lower these specific blood markers more effectively than short-term extreme diets in overweight middle-aged adults.

Long-term weight loss (2 years) is equivalent between low-carbohydrate and low-fat diets when both are combined with comprehensive behavioral interventions.

If you are trying to lose weight long-term, do not obsess over whether you must cut carbs or fat. Focus on getting comprehensive behavioral support (counseling, tracking, lifestyle coaching). Both low-carb and low-fat diets resulted in the same amount of weight loss (7%) over two years when behavioral support was included. The specific macronutrient ratio is less important than the behavioral adherence supported by the program.

A low-carbohydrate diet provides superior long-term improvements in HDL cholesterol compared to a low-fat diet, even when weight loss is equivalent.

If you choose a low-carbohydrate diet, expect a significant boost in HDL (good) cholesterol, roughly double that of a low-fat diet. This metabolic benefit persists for at least 2 years. While weight loss is the same as low-fat, the lipid profile improvement is superior.

A ketogenic diet significantly improves quality of life (QoL) and reduces fatigue symptoms in individuals with overweight, particularly those with high baseline fatigue.

If you are overweight and struggle with fatigue, a ketogenic diet may help boost your energy and overall quality of life. This benefit seems most pronounced if you already feel fatigued. Stick to the diet for at least three months, ensure you are in ketosis, and monitor how your energy levels change.

Weight loss acts as a significant moderator for the effect of combined interventions on visceral fat area (VFA), but not for liver fat or intramuscular triglycerides (IMTG).

Losing weight helps reduce visceral fat, but it may not be enough to reduce liver or muscle fat. If you have concerns about liver or muscle fat, you may need additional strategies beyond just weight loss.

Long-term weight loss via lifestyle interventions reduces cervical subcutaneous adipose tissue (cervical-SAT) significantly, whereas chin subcutaneous adipose tissue (chin-SAT) shows a significant initial reduction but rebounds to baseline levels after 18 months.

If you are losing weight, expect your neck fat to decrease more sustainably than chin fat. While you may see an initial reduction in chin fat, it is likely to return as you maintain your weight long-term, whereas neck fat reduction is more persistent. This does not mean weight loss is ineffective, but rather that fat distribution changes are depot-specific.

Reduction in chin subcutaneous adipose tissue (chin-SAT) is independently associated with improvements in glycemic control (fasting glucose, HbA1c, HOMA-IR) and lipid profiles, even after adjusting for changes in visceral adipose tissue (VAT) and waist circumference.

Losing chin fat may be a sign of improving metabolic health, specifically insulin sensitivity. While you cannot spot-reduce, the reduction of this specific fat depot correlates with better blood sugar control, independent of how much belly fat you lose.

Reduction in cervical subcutaneous adipose tissue (cervical-SAT) is independently associated with improvements in lipid profiles (triglycerides, LDL-C, cholesterol/HDL ratio) and leptin levels, independent of visceral adipose tissue (VAT).

Losing neck fat may be a sign of improving metabolic health, specifically lipid profiles and leptin sensitivity. While you cannot spot-reduce, the reduction of this specific fat depot correlates with better blood lipid control, independent of how much belly fat you lose.

Time-restricted eating (TRE) combined with caloric restriction (CR) does not yield superior weight loss compared to caloric restriction alone in overweight and obese women.

If you are already restricting calories to lose weight, adding a strict eating window may not give you any extra weight loss benefit. You can achieve similar results with just calorie control.

A 1-month very-low-calorie ketogenic diet (VLCKD) in women with obesity causes a significant reduction in 24-hour energy expenditure (24hEE) and sleeping metabolic rate (SMR), primarily driven by the loss of lean soft tissue (LST) rather than metabolic adaptation alone.

If you follow a very-low-calorie ketogenic diet, expect your daily calorie burn to drop by about 10% after a month. This isn't just 'metabolic damage'; it's largely because you are lighter and have lost some muscle. To protect your metabolism, prioritize the protein target (1.2-1.5g/kg ideal body weight) and incorporate light resistance or walking to preserve lean tissue.

A 1-month VLCKD shifts substrate oxidation to favor fat and protein, resulting in a 62% fat mass loss and 38% lean soft tissue loss of total weight lost.

On a VLCKD, you will lose fat and muscle. In this study, 38% of the weight lost was lean tissue. To minimize this, ensure you are eating enough protein (1.2-1.5g/kg ideal body weight) and engaging in resistance exercise.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) achieve 10-15% weight loss and superior metabolic improvements compared to lifestyle changes alone, but are recommended for non-responders or those with comorbidities.

If lifestyle changes alone do not achieve sufficient weight loss or if you have obesity-related comorbidities, discuss GLP-1 receptor agonists (like semaglutide or liraglutide) with your doctor. These medications can lead to 10-15% weight loss and significant metabolic improvements, though they may cause gastrointestinal side effects. They are most effective when combined with lifestyle modifications.

Intermittent fasting (IF) produces weight loss and metabolic improvements comparable to continuous caloric restriction (CCR) in adults with overweight or obesity, without providing superior benefits.

If you are overweight or obese, intermittent fasting is a viable option for weight loss, but do not expect it to work better than simply eating fewer calories every day. Studies show that IF and continuous calorie restriction lead to similar weight loss (around 5% of body weight) and metabolic improvements over a year. Choose the method that you can stick with long-term, as adherence is key.

Lactobacillus sp. supplementation is safe and well-tolerated in non-comorbid obese individuals, with no significant adverse events reported.

You can take Lactobacillus probiotics with confidence regarding safety. Clinical trials show they are well-tolerated with no significant increase in side effects compared to a placebo.

Tirzepatide produces significant weight loss (mean 18.73%) and improves quality of life in overweight or obese adults without diabetes, but significantly increases the risk of adverse events compared to placebo.

Tirzepatide is a highly effective treatment for weight loss in non-diabetic overweight or obese adults, producing an average 18.73% body weight loss. However, it comes with a significantly higher risk of adverse events, particularly gastrointestinal issues, compared to placebo. Patients should be monitored closely for these side effects.

Increasing exercise volume from 3 sessions/week to 6 sessions/week further reduces fat mass and visceral adipose tissue, although the difference in fat-free mass preservation between 3 and 6 sessions was not statistically significant for absolute fat-free mass kg.

Even 3 days of exercise per week, combined with diet, significantly improves fat loss compared to diet alone. You do not need 6 days to see benefits, but 6 days provides greater fat loss and better muscle preservation.

Higher baseline body weight and BMI strongly predict greater absolute weight loss and fat mass reduction on a very low-calorie ketogenic diet (VLCKD), with men losing significantly more weight than women.

If you have a higher starting weight, you are likely to lose more absolute weight on a VLCKD than someone with a lower starting weight. Men also tend to lose more weight than women on this specific protocol. Use your baseline weight as a predictor of success rather than comparing yourself to others with different starting points.

Intermittent fasting downregulates enteroendocrine signaling, specifically GLP-1, GCG, and PYY, while upregulating PPAR-α, which correlates with improved lipid profiles.

The molecular changes observed (PPAR-α upregulation, GLP-1 downregulation) suggest that IF works by altering how your body processes fats and regulates hormones, not just by restricting calories. This may inform future targeted therapies.